Aduro Biotech Announces Appointment of Leading Immunotherapy and Oncology Experts to Scientific Advisory Board
January 26 2017 - 8:00AM
Aduro Biotech, Inc. (Nasdaq:ADRO), a biopharmaceutical company with
three distinct immunotherapy technologies, announced today the
appointment of five key opinion leaders to its scientific advisory
board, who join four existing leading clinicians, researchers and
scientists. Newly appointed members include: Thomas Gajewski, M.D.,
Ph.D., Darren Higgins, Ph.D., F. Stephen Hodi, M.D., Wiebe Olijve,
Ph.D., and David H. Raulet, Ph.D.
“We are thrilled to expand our scientific expertise with five
additional leading researchers and clinicians in the fields of
immunology and oncology,” said Thomas W. Dubensky Jr., Ph.D., chief
scientific officer of Aduro Biotech. “We look forward to
leveraging the expanded, collective knowledge of our scientific
advisory board as we seek to enhance our leadership in the field of
immunotherapy and make new therapeutic treatment options a reality
for patients who need them.”
Aduro’s scientific advisory board now includes nine leading
immunology and oncology experts:
- Drew Pardoll (chairman), M.D., Ph.D., Abeloff
Professorship of Oncology, Director of the Bloomberg-Kimmel
Institute for Cancer Immunotherapy and Director of the Cancer
Immunology Program at the Johns Hopkins School of Medicine; focus
on mechanisms by which cancer cells evade the immune system;
- Thomas Gajewski, M.D., Ph.D., leader of the
Immunology and Cancer program at the University of Chicago
Comprehensive Cancer Center, director of Melanoma Oncology and
professor at the Ben May Cancer Institute; focus on the role of
Stimulator of Interferon Genes (STING) and immunity;
- John Hearst, Ph.D., (emeritus member)
co-founder of Cerus Corporation and professor emeritus at the
University of California, Berkeley;
- Darren Higgins, Ph.D., professor of
Microbiology and Immunobiology at Harvard Medical School; focus on
host-pathogen interactions and development of protective
immunity;
- F. Stephen Hodi, M.D., director of the
Melanoma Center and the Center for Immuno-Oncology at
Dana-Farber/Brigham and Women’s Cancer Center, the Sharon Crowley
Martin Chair in Melanoma at Dana-Farber Cancer Institute and
professor of Medicine at Harvard Medical School;
- John Mekalanos, Ph.D., Adele H. Lehman
Professor of Microbiology and Immunobiology at Harvard Medical
School; focus on bacterial pathogenesis and host-pathogen
interactions;
- Wiebe Olijve, Ph.D., Microbiologist and former
vice president of Research at Organon and site-head of
Schering-Plough BioPharma, emeritus professor of Applied Biology
(Nijmegen), co-founder and former CEO of BioNovion (now Aduro
Biotech Europe);
- Daniel A. Portnoy, Ph.D., professor at the
University of California, Berkeley with joint appointments in the
divisions of Biochemistry and Molecular Biology, Immunology and
Pathogenesis, Infectious Diseases and Microbial Biology and holds
the Edward E. Penhoet Distinguished Chair in Global Public Health
and Infectious Diseases; focus on Listeria monocytogenes;
- David H. Raulet, Ph.D., tumor immunologist,
director of the University of California, Berkeley's Immunotherapy
and Vaccine Research Initiative, Esther and Wendy Schekman Chair in
Basic Cancer Biology and professor of Immunology and Pathogenesis
in the department of Molecular and Cellular Biology at the
University of California, Berkeley; focus on tumor
immune-surveillance and immunotherapy for cancer.
Additionally, Aduro Board of Director members Frank McCormick,
Ph.D., F.R.S., D.Sc., and Stephen A. Sherwin, M.D., participate in
Aduro’s scientific advisory board in their capacity as members of
the Science and Technology Committee of the board of directors.
More information about members of the Aduro scientific advisory
board, can be found on the Aduro website.
About Aduro Aduro Biotech, Inc. is an
immunotherapy company focused on the discovery, development and
commercialization of therapies that transform the treatment of
challenging diseases. Aduro's technology platforms, which are
designed to harness the body's natural immune system, are being
investigated in cancer indications and have the potential to expand
into autoimmune and infectious diseases. Aduro's LADD technology
platform is based on proprietary attenuated strains of Listeria
that have been engineered to express tumor-associated antigens to
induce specific and targeted immune responses. This platform is
being developed as a treatment for multiple indications, including
ovarian, lung and prostate cancers, mesothelioma and glioblastoma.
Additionally, a personalized form of LADD, or pLADD, is being
developed utilizing tumor neoantigens that are specific to an
individual patient’s tumor. Aduro's STING Pathway Activator
platform is designed to activate the intracellular STING receptor,
resulting in a potent tumor-specific immune response. ADU-S100 is
the first STING Pathway Activator compound to enter the clinic and
is currently being evaluated in a Phase 1 study in patients with
cutaneously accessible metastatic solid tumors or lymphomas.
Aduro’s B-select monoclonal antibody platform includes a number of
immune modulating assets in research and preclinical development.
Aduro is collaborating with leading global pharmaceutical companies
to expand its products and technology platforms. For more
information, please visit www.aduro.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements regarding our intentions or current expectations
concerning, among other things, our technology platforms, plans,
and the potential for eventual regulatory approval of our product
candidates. In some cases, you can identify these statements by
forward-looking words such as “may,” “will,” “continue,”
“anticipate,” “intend,” “could,” “project,” “seek”, “expect” or the
negative or plural of these words or similar expressions.
Forward-looking statements are not guarantees of future performance
and are subject to risks and uncertainties that could cause actual
results and events to differ materially from those anticipated,
including, but not limited to, our history of net operating losses
and uncertainty regarding our ability to achieve profitability, our
ability to develop and commercialize our product candidates, our
ability to use and expand our technology platforms to build a
pipeline of product candidates, our ability to obtain and maintain
regulatory approval of our product candidates, our inability to
operate in a competitive industry and compete successfully against
competitors that have greater resources than we do, our reliance on
third parties, and our ability to obtain and adequately protect
intellectual property rights for our product candidates. We
discuss many of these risks in greater detail under the heading
“Risk Factors” contained in our quarterly report on Form 10-Q for
the quarter ended September 30, 2016, which is on file
with the Securities and Exchange Commission. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. We assume no obligation
to update our forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Contact:
Sylvia Wheeler
SVP, Corporate Affairs
510 809 9264
Media Contact:
Susan Lehner
510 809 2137
press@aduro.com
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aduro Biotech (NASDAQ:ADRO)
Historical Stock Chart
From Apr 2023 to Apr 2024